Laxminarayan Bhat, PhD
Dr. Bhat founded Reviva Pharmaceuticals (Reviva) in 2006 and since its inception, Reviva has advanced extremely rapidly under his leadership, with a portfolio of proprietary compounds at different stages in a pipeline encompassing chronic diseases in large therapeutic areas such as CNS, metabolic, cardiovascular and pain. Dr. Bhat has developed and implemented innovative financing and business models with strategies that have greatly accelerated the drug discovery and development process, resulting in significant savings of time and costs but without sacrificing quality.
Dr. Bhat has over 20 years’ experience in drug discovery and development and prior to founding Reviva, he held research positions at XenoPort, ARYx Therapeutics and Higuchi Biosciences Center in the United States. Dr. Bhat has received a global post-doctoral training at the University of Kansas, USA, the Georg-August-Universität, Göttingen, Germany and the Université du Maine, France. In 1995, he was selected for the Alexander von Humboldt fellowship, an internationally recognized award for young scientists to pursue advanced research in Germany. Dr. Bhat received his Ph.D. in synthetic organic chemistry from the Central University (NEHU), India and has authored over 25 research papers published in peer-reviewed scientific journals. Dr. Bhat is an inventor on more than 100 filed patents and over 45 granted patents.